Combined assessment of TGF-beta-1 and alpha-fetoprotein values improves specificity in the diagnosis of hepatocellular carcinoma and other chronic liver diseases in Malaysia

Medical Journal of Malaysia

Volumn 64, Issue 3, 2009, Pages 223-227

  Yasmin Anum, Mohd Yusof ^a   Looi, M L ^a   Nor Aini, A H ^a   Merican, I ^b   Wahidah, A ^c   Mohd Radzi, A H ^d   Nor Azizah, A ^e   Othman, N H ^f  

^a UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

^b MINISTRY OF HEALTH   (Malaysia)

^c Hospital Tengku Ampuan Rahimah   (Malaysia)

^d HOSPITAL SULTANAH BAHIYAH   (Malaysia)

^e SCHOOL OF HEALTH SCIENCES   (Malaysia)

^f SCHOOL OF MEDICAL SCIENCES   (Malaysia)

Author keywords

AFP; Hepatocellular carcinoma; TGF 1; Tumour marker

Indexed keywords

ALPHA FETOPROTEIN; MOLECULAR MARKER; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SPECIFICITY; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALAYSIA; PROTEIN BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CHRONIC DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LIVER DISEASES; LIVER NEOPLASMS; MALAYSIA; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKERS, BIOLOGICAL;

EID: 77649123407     PISSN: 03005283     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Kew MC. Epidemiology of hepatocellular carcinoma. Toxicol 2002; 35; 181-82.
2. Lim CC, Halimah Y. 2nd Report of National Cancer Registry of Cancer Incidence in Malaysia 2003.
3. Tsai JF, Chang WY, Jeng JE, Ho MS, Lin ZY, Tsai JH. Hepatitis B and C virus infection as risk factors for liver cirrhosis and cirrhotic hepatocellular carcinoma: A case-control study. Liver 1994; 14: 98-102.
4. Tsai JF, Chang WY, Jeng JE, Ho MS, Lin ZY, Tsai JH. Effects of hepatitis C and B viruses infection on the development of hepatocellular carcinoma. J Med Virol 1994; 44: 92-95.
5. Jeffers L. Hepatocellular carcinoma: an emerging problem with hepatitis C. J Natl Med Assoc 2000; 92: 369-71.
6. Tsai JF, Jeng JE, Chang WY et al. Additive effect modification of hepatitis B surface antigen and e antigen on the development of hepatocellular carcinoma. Br J Cancer 1996; 73: 1498-502.
7. Tsai JF, Margolis HS, Jeng JE et al. Circulating immune complexes in chronic hepatitis related to hepatitis C and B viruses infection. Clin Immunol Immunopathol 1995; 75: 39-44.
8. Tsai JF, Margolis HS, Jeng JE et al. Hepatitis B surface antigen and immunoglobulin-specific circulating immune complexes in acute hepatitis B virus infection. Clin Immunol Immunopathol 1996; 80: 278-82.
9. Thompson Coon J, Rogers G, Hewson P et al. Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis. Br J Cancer 2008; 98: 1166-75.
10. Tsai JF, Chang WY, Jeng JE, Ho MS, Lin ZY, Tsai JH. Frequency of raised AFP level among Chinese patients with hepatocellular carcinoma related to hepatitis B and C. Br J Cancer 1994; 69: 1157-59.
11. Lopez PM, Villanueva A, Llovet JM. Evidence-Based Management of Hepatocellular Carcinoma - An Updated Analysis of Randomized Controlled Trials. Aliment Pharmacol Ther. 2006; 23(11): 1535-47.
12. Spangenberg HC, Thimme R, Blum HE. Serum markers of hepatocellular carcinoma. Seminars in liver disease. 2006; 26: 385-90.
13. Li D, Mallory T, Satomura S. AFP-L3: a new generation of tumour marker for hepatocellular carcinoma. Clin Chim Acta 2001; 313: 15-19.
14. Mohd Yusof YA, Baba A, Salleh MN, Ramankutty M. Prealbumin rather than albumin is a more sensitive indicator of acute liver disease. Malaysian J Pathol 1993; 15: 147-50.
15. Liebman HA. Isolation and characterization of a hepatoma-associated abnormal (des-gamma-carboxy) prothrombin. Cancer Res 1989; 49: 6493-97.
16. Cui R, He J, Zhang F et al. Diagnostic value of protein induced by vitamin K absence (PIVKA II) and hepatoma-specific band of serum gamma-glutamyl transferase (GGT II) as hepatocellular carcinoma markers complementary to alpha-fetoprotein. Br J Cancer 2003; 88: 1878-82.
17. Liebman HA, Furie BC, Tony MJ et al. Des-gamma -carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 1984; 310: 1427-31.
18. Marrero JA, Su GL, Wei W et al. Des-gamma carboxyprotrhombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatol 2003; 37: 1114-21.
19. Yao DF, Jiang DR, Huang ZW et al. Abnormal expression of hepatoma specific ?-glutamyl transferase and alteration of ?-glutamyl transferase gene methylation status in patients with hepatocellular carcinoma. Cancer 2000; 88: 761-69.
20. Kim HG, Chung YH, Song BC et al. Expression of transforming growth factor beta-1 in chronic hepatitis and hepatocellular carcinoma associated with hepatitis C virus infection. Korean J Intern Med 2000; 15: 165-70.
21. Song B-C, Chung Y-H, Kim JA et al. Transforming growth factor-β1 as a useful serologic marker of small hepatocellular carcinoma. Cancer 2002; 94: 175-80.
22. Mohd Yusof YA, Salleh MN, Abdullah NA. Elevation of serum transforming growth factor (TGF)-beta-1 and reduction of serum pre-albumin (PAB) and its relationship to serum alpha-fetoprotein (AFP) levels in patients with hepatocellular carcinoma. Malaysian J Biochem and Molec Biol 1997; 2: 18-22.
23. Elliott RL, Blobe GC. Role of transforming growth factor beta in human cancer. J Clin Oncology 2005; 23: 2078-93.
24. Cross M, Dexter TM. Growth factors in development, transformation and tumorigenesis. Cell 1991; 64: 271-80.
25. Bedossa P, Paradis V. Transforming growth factor-beta (TGF-beta): A key role in liver fibrogenesis. J Hepatol 1995; 22: Suppl 2: 37-42.
26. Wollenberg GK, Semple E, Quinn BA, Hayes MA. Inhibition of proliferation of normal, preneoplastic, and neoplastic rat hepatocytes by transforming growth factor-beta. Cancer Res 1987; 47: 6595-99.
27. Sacco R, Leud D, Tortorella C et al. Transforming growth factor beta-1 and soluble Fas serum levels in hepatocellular carcinoma. Cytokine 2000; 12: 811-14.
28. Liaw YF, Tai DI, Chu CM et al. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. Gasteroenterol 1986; 90: 263-7.
29. Bissell DM, Roulot D, George J. Transforming growth factor beta and the liver. Hepatol 2001; 34: 859-67.
30. Okumoto K, Hattori E, Tamura K et al. Possible contribution of circulating transforming growth factor-beta 1 to immunity and prognosis in unresectable hepatocellular carcinoma. Liver Int 2004; 24: 21-28.
31. Colombo M, de Franchis R, Del Ninno E et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Eng J Med 1991; 325: 675-80.
32. Pateron D, Ganne N, Trinchet JC et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 1994; 20: 65-71.
33. Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA. Immunohistochemical staining for transforming growth fartor beta 1 associates with disease progression in human breast cancer. Cancer Res 1992; 52: 6949-52.
34. Shim KS, Kim KH, Han WS, Park EB. Elevated serum levels of transforming growth factor-beta 1 in patients with colorectal carcinoma: Its association with tumor progression and its significant decrease after curative surgical resection. Cancer 1999; 85: 554-61.
35. Barthelemy-Brichant N, David JL, Bosquee L et al. Increased TGF-beta 1 plasma level in patients with lung cancer: potential mechanisms. Eur J Clin Invest 2002; 32: 193-98.
36. Dong ZZ, Yao DF, Yao M et al. Clinical impart of plasma TGF β1 and circulating TGF β1mRNA in diagnosis of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2008; 7: 288-95.
37. Castilla A, Prieto J, Fausto N. Transforming growth factor β1 and α in chronic liver disease:effects of interferon alpha therapy. N Eng J Med 1991; 324: 934-40.
38. Bedossa P, Peltier E, Teris B, Franco D, Poynard T. Transforming growth factor beta-1 (TGF β1) and TGF β1receptors in normal, cirrhotic, and neoplastic human livers. Hepatol 1995; 21: 760-65.
39. Hsia CC, Evarts RP, Nakatsuka H, Marsden ER, Thorgeisson SS. Occurrence of oval-type cells in hepatitis B virus-associated human hepatocarcinogenesis. Hepatol 1992; 16: 1327-33.
40. Lowes KN, Brennan BA, Yeoh GC, Olynyk JK. Oval cell numbers in human chronic liver diseases are directly related to disease severity. Amer J of Pathol 1999; 154: 537-40.
41. Dekai Q, Xiong M, Yansken P, Xiaoyu C, Yao S. Localization and quantitative study of hepatic oval cells in patients with chronic liver diseases: a pathological analysis of 29 liver specimens. Chinese J Digestive Disease 2002; 2: 78-82.
42. Flisiak R, Pytel-Krolczuk B, Prokopowicz D. Circulating transforming growth factor β1 as an indicator of hepatic function impairment in liver cirrhosis. Cytokine 2000; 12: 677-81.
43. Shirai Y, Kawata S, Tamura S et al. Plasma transforming growth fartor beta-1 in patient with hepatocellular carcinoma, comparison with chronic liver disease. Cancer 1994; 73: 2275-78.
44. Ito N, Kawata S, Tamura S et al. Elevated levels of TGF-beta-1 messenger RNA and its polypeptide in human hepatocellular carcinoma. Cancer Res 1991; 51: 4080-83.